Vyne Therapeutics Inc. (VYNE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
VYNE Chart
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.
Vyne Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeffrey Gundlach DoubleLine Capital LP | 22,400 | $2.57M | $17,357.76 | -$2.55M | -99.32% |
| RS Richard Slavik Newbridge Financial Services Group Inc. | 10 | $3.35 | $7.68 | $4.33 | 129.25% |
| KJ Ken Joseph Braidwel LLP | 916,077 | $547,356.01 | $704,280 | $156,923.99 | 28.67% |
| AH Anders Hove Acorn Capital Advisors LLC | 1,425 | $2,251.5 | $1,097.11 | -$1,154.39 | -51.27% |
| LC Leslie Childs MB Levis & Associates LLC | 1,041 | $3,206 | $802.51 | -$2,403.49 | -74.97% |
Vyne Therapeutics Inc. (VYNE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vyne Therapeutics Inc. ever had a stock split?
Vyne Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | David T. Domzalski CEO | NASDAQ (CM) Exchange | 92941V308 CUSIP |
| US Country | 10 Employees | 22 Jul 2026 Last Dividend | 13 Feb 2023 Last Split | 25 Jan 2018 IPO Date |
Overview
VYNE Therapeutics Inc., initially established as Menlo Therapeutics Inc. in 2003, underwent a name change in September 2020 and is now known as VYNE Therapeutics Inc. The company operates from Bridgewater, New Jersey, focusing on the pharmaceutical development of treatments aimed at immuno-inflammatory conditions. They leverage advanced therapeutic research and clinical trials to create solutions targeting a range of skin diseases and inflammatory conditions, positioning themselves at the forefront of dermatological and immuno-inflammatory health advancements.
Products and Services
- FCD105: This topical combination foam has successfully completed Phase III clinical trials, proving its efficacy in treating moderate-to-severe acne vulgaris. This product represents VYNE Therapeutics' aim to address common yet challenging dermatological conditions with innovative, effective treatments.
- FMX114: Currently in Phase IIa preclinical trial, FMX114 is a combination treatment consisting of tofacitinib, designed for patients with mild-to-moderate atopic dermatitis. This indicates the company’s expansion into broader dermatological areas, showcasing their commitment to addressing various skin health needs.
- VYN201: A bromodomain and extra-terminal (BET) inhibitor, VYN201 is under development for addressing a wide range of immuno-inflammatory diseases, including certain skin conditions. This treatment seeks to provide a new avenue for the management and relief of immuno-inflammatory diseases.
- VYN202: This compound is a BET inhibitor that selectively targets bromodomain 2. VYN202’s development underlines VYNE Therapeutics’ ambition to offer targeted treatments for immuno-inflammatory conditions, potentially revolutionizing how these diseases are approached and managed in the clinical setting.
